RxDoctor Payments Data

Shanmuga Sundaram Pudunagar Subbiah, MD

Hematology & Oncology · Upland, CANPI 1699968503

Payments from drug & device makers

$77,570in general payments, 2019–2025

Across 288 payments — averaging $269.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$41K
  • Exelixis Inc.$9K
  • Novartis$8K
  • Incyte Corporation$3K
  • Daiichi Sankyo Inc.$3K
  • Pfizer$3K
  • plus $9K from 30 others

What the payments were for

  • Consulting fees$31,62241%
  • Speaking & faculty fees$33,19143%
  • Travel & lodging$5,1117%
  • Food & beverage$4,7956%
  • Education$8211%
  • Other$2,0303%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$77,570 in reported general payments places this provider in the 70th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$560,319
Medicare patients
770
Services billed
5,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate44$742,164
LenvimaLenvatinib Mesylate13$305,151
PomalystPomalidomide13$288,570
RevlimidLenalidomide14$276,184
ErleadaApalutamide15$226,392
CalquenceAcalabrutinib Maleate15$219,580
ImbruvicaIbrutinib13$212,913
Lenalidomide16$163,915
BrukinsaZanubrutinib12$155,842
VenclextaVenetoclax11$78,808
EliquisApixaban74$54,527
XareltoRivaroxaban29$29,696
Exemestane11$3,190
Tamoxifen Citrate74$1,669
Megestrol Acetate25$1,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Calquence$41,079$961,74359 claims
Eisai Inc.Lenvima$21$305,15113 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$2,125$288,57013 claims
Bristol Myers SquibbRevlimid$1,655$276,18414 claims
Johnson & JohnsonErleada, Xarelto$284$256,08844 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$18$212,91313 claims
Beigene USA, Inc.Brukinsa$675$155,84212 claims
AbbVieVenclexta$25$78,80811 claims
PfizerEliquis$3,261$54,52774 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Upland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →